​

Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?

OverviewForecastRevenueFinancialsChart

Celldex Therapeutics Ownership Summary

Celldex Therapeutics is owned by 109.48% institutional investors, 0.19% insiders. Wellington management group llp is the largest institutional shareholder, holding 13.54% of CLDX shares. BB Biotech AG Ord is the top mutual fund, with 4.63% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCelldex Therapeutics109.48%0.19%-9.67%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wellington management group llp8.98M13.54%$226.82M
Kynam capital management, lp6.10M9.19%$124.15M
Blackrock funding, inc. /de5.55M8.36%$112.94M
Blackrock4.69M7.97%$173.61M
Fmr4.86M7.33%$122.75M
Vanguard group3.88M5.86%$98.10M
Price t rowe associates inc /md/3.56M5.37%$89.89M
Bellevue group3.31M4.98%$67.31M
State street3.23M4.88%$81.75M
Point72 asset management2.80M4.22%$57.02M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp6.10M13.37%$124.15M
5am venture management497.27K3.00%$12.57M
Tsp capital management group371.43K2.37%$7.56M
Sphera funds management419.54K2.00%$8.54M
Vestal point capital, lp1.75M1.88%$35.61M
Novo1.20M1.72%$24.42M
Eversept partners, lp838.74K1.57%$17.07M
Bellevue group3.31M1.48%$67.31M
Logos global management lp600.00K1.35%$12.21M
Deep track capital, lp2.00M1.31%$40.70M

Top Buyers

HolderShares% AssetsChange
Vestal point capital, lp1.75M1.88%1.55M
State street3.23M0.00%749.80K
Price t rowe associates inc /md/3.56M0.01%676.77K
Logos global management lp600.00K1.35%600.00K
Baker bros. advisors lp665.37K0.13%417.73K

Top Sellers

HolderShares% AssetsChange
Eventide asset management1.36M0.48%-2.40M
T. rowe price investment management---1.70M
Commodore capital lp---1.62M
Jennison associates---1.32M
Fmr4.86M0.01%-1.17M

New Positions

HolderShares% AssetsChangeValue
Logos global management lp600.00K1.35%600.00K$12.21M
Tfg asset management gp192.00K1.20%192.00K$4.85M
Highvista strategies106.55K0.80%106.55K$2.17M
Y-intercept (hong kong)58.40K0.03%58.40K$1.19M
Perbak capital partners llp40.41K0.19%40.41K$822.34K

Sold Out

HolderChange
Assetmark-1.00
Umb bank, n.a.-2.00
Nelson, van denburg & campbell wealth management group-10.00
Householder group estate & retirement specialist-11.00
Coldstream capital management-12.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251843.95%72,686,2280.53%1090.92%11325.56%41-22.64%
Mar 31, 2025180-5.76%73,628,401-0.08%1100.90%90-11.76%5510.00%
Dec 31, 2024122-38.69%40,075,962-44.20%600.52%68-28.42%29-47.27%
Sep 30, 20241996.42%71,815,5513.19%1080.78%95-8.65%5514.58%
Jun 30, 2024187-8.33%69,597,4190.41%1180.85%104-18.75%4811.63%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord3.07M4.63%-
Eventide Gilead N2.38M3.59%-
Vanguard Total Stock Mkt Idx Inv2.14M3.22%-44.27K
Vanguard Health Care Inv2.12M3.19%-2.43M
Vanguard US Total Market Shares ETF2.07M3.11%2.12K
iShares Russell 2000 ETF1.54M2.32%-29.19K
US Small-Cap Growth II Equity Comp1.39M2.09%-121.70K
T. Rowe Price New Horizons1.39M2.09%-157.87K
Eventide Healthcare & Life Sciences I1.36M2.04%-
Polar Capital Biotech S Inc1.23M1.84%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$10.93K
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$8.17K
Nov 11, 2024Marucci Anthony S PRESIDENT & CEOBuy$308.43K
Jun 14, 2024Martin Samuel Bates SVP AND CFOSell$608.31K
Jun 14, 2024Crowley Elizabeth SR. VP & CPDOSell$1.05M

Insider Transactions Trends

DateBuySell
2025 Q3-2
2025 Q2--
2024 Q41-
2024 Q2-12
2024 Q1--

CLDX Ownership FAQ

Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 109.48%, followed by 0.19% insiders and -9.67% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 306.59%, which Celldex Therapeutics falls below.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Wellington management group llp (8.98M shares, 13.54%), Kynam capital management, lp (6.1M shares, 9.19%), and Blackrock funding, inc. /de (5.55M shares, 8.36%). Together, they hold 31.09% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 13.37% of its assets in 6.1M Celldex Therapeutics shares, valued at 124.15M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Celldex Therapeutics shares, with 4.63% of its total shares outstanding invested in 3.07M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools